Fustibal is a biotechnology startup focused on fostering affordable healthcare through simpler science. Our mission is to develop antibody-based nanomedicines for multi-targeted cancer therapy. Our oncology therapeutics functionalize the tumor-targeting capability of antibodies with the large drug payload and the prolonged circulation time of nanomedicines for synergistic therapeutic effects. Through data-based computational platforms and modular drug design, we repurpose and improve existing chemical and biological pharmaceuticals for efficacy, safety, and unmet medical needs. Combining our science and business expertise, we offer the commercial opportunity to bring to market innovative lifesaving medicines to recapture prevailing markets and to capture new ones.

Throughout his research career in academia and biotechnology startups, David has investigated targeted drug delivery systems for the treatment of cancer and blood disorders with focuses on chemical and biological pharmaceuticals, nanomedicines, gene therapy, RNA interference, and antibodies. He has worked on multiple NIH-funded and FDA-funded projects on innovative drug development and the assessment of bioequivalence of complex medicines. His extensive research experience includes drug development, molecular biology, cell culture, assay development, microscopy, mathematical modeling, drug release kinetics, pharmacokinetics, biodistribution, and preclinical therapeutic studies. David received his doctorate from the University of California San Francisco and Berkeley Joint Graduate Group in Bioengineering with a minor in the Management of Technology from the Haas School of Business and a Bachelor of Science in Bioengineering at Rice University. He has a background in pharmaceutical science, bioengineering, mathematics, computational science, and business.

Fustibal is an affiliate of the California Institute for Quantitative Biosciences (QB3), a nonprofit research and technology commercialization institute spanning the University of California San Francisco (UCSF), Berkeley, and Santa Cruz. Our technical team has access to research core facilities in genomics, proteomics, imaging, structure determination, high-throughput screening, informatics, bioengineering, cell culture, preclinical therapeutics, and more.